These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23540512)

  • 41. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy.
    Desai B; Freeman E; Huang E; Hung A; Knapp E; Breunig IM; McPherson ML; Shaya FT
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):203-9. PubMed ID: 24524594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
    J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].
    Takagi Y; Aruga E
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):205-211. PubMed ID: 29483406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacology update: tapentadol for neuropathic pain.
    Pierce DM; Shipstone E
    Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.
    Mercadante S; Prestia G; Ranieri M; Giarratano A; Casuccio A
    Support Care Cancer; 2013 Jul; 21(7):1853-9. PubMed ID: 23400316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain.
    Mercadante S; Salvaggio L; Dardanoni G; Agnello A; Garofalo S
    J Pain Symptom Manage; 1998 Feb; 15(2):76-81. PubMed ID: 9494305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Tapentadol on Splenic Cytokine Production in Mice.
    Franchi S; Amodeo G; Gandolla M; Moschetti G; Panerai AE; Sacerdote P
    Anesth Analg; 2017 Mar; 124(3):986-995. PubMed ID: 27997452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tapentadol (Palexia) for moderate to severe acute pain.
    Drug Ther Bull; 2012 Mar; 50(3):30-3. PubMed ID: 22419754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opioid conversion ratios used in palliative care: is there an Australian consensus?
    Syrmis W; Good P; Wootton J; Spurling G
    Intern Med J; 2014 May; 44(5):483-9. PubMed ID: 24589128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
    Binhas M; Krakowski I; Marty J
    Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
    Cepeda MS; Fife D; Ma Q; Ryan PB
    J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
    J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.